The process of planning the preclinical trial, funding it, starting it, ending it, gathering the data and submitting the ODD application will take longer than we think. And remember, an ODD doesn't guarantee value or success in humans. The ODD just gives advantages to drugs which MIGHT work for a rare indication. With that said, an ODD will not double the market cap of CYDY. The human trial for gvhd would still take funding and time to prove results.
News 
Market Data 
Discover 
